LncRNA as a regulator in the development of diabetic complications

Mengrou Geng; Wei Liu; Jinjie Li; Ge Yang; Yuan Tian; Xin Jiang; Ying Xin

doi:10.3389/fendo.2024.1324393

LncRNA as a regulator in the development of diabetic complications

Front Endocrinol (Lausanne). 2024 Feb 8:15:1324393. doi: 10.3389/fendo.2024.1324393. eCollection 2024.

Authors

Mengrou Geng^{1

2}, Wei Liu², Jinjie Li², Ge Yang², Yuan Tian², Xin Jiang^{1

3

4}, Ying Xin²

Affiliations

¹ Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University and College of Basic Medical Science, Jilin University, Changchun, China.
² Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Science, Jilin University, Changchun, China.
³ Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, China.
⁴ National Health Commission (NHC) Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China.

Abstract

Diabetes is a metabolic disease characterized by hyperglycemia, which induces the production of AGEs, ROS, inflammatory cytokines, and growth factors, leading to the formation of vascular dysfunction and target organ damage, promoting the development of diabetic complications. Diabetic nephropathy, retinopathy, and cardiomyopathy are common complications of diabetes, which are major contributors to disability and death in people with diabetes. Long non-coding RNAs affect gene transcription, mRNA stability, and translation efficiency to influence gene expression for a variety of biological functions. Over the past decade, it has been demonstrated that dysregulated long non-coding RNAs are extensively engaged in the pathogenesis of many diseases, including diabetic complications. Thus, this review discusses the regulations of long non-coding RNAs on the primary pathogenesis of diabetic complications (oxidative stress, inflammation, fibrosis, and microvascular dysfunction), and some of these long non-coding RNAs may function as potential biomarkers or therapeutic targets for diabetic complications.

Keywords: diabetic cardiomyopathy; diabetic nephropathy; diabetic retinopathy; long non-coding RNAs; microRNA.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Cytokines
Diabetes Complications* / genetics
Diabetes Mellitus* / genetics
Diabetic Nephropathies* / genetics
Humans
Hyperglycemia*
RNA, Long Noncoding* / genetics

Substances

RNA, Long Noncoding
Cytokines

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by the National Natural Science Foundation of China (No. 82170369), the Jilin Provincial Science and Technology Foundation (Nos.20210509003RQ and 20230402002GH).